Research programme: antiviral and anticancer ribonucleases - Tamir Biotechnology

Drug Profile

Research programme: antiviral and anticancer ribonucleases - Tamir Biotechnology

Alternative Names: AC CJ-001; AC-03-636; Amphinase 3; Natural P31 - Tamir; rAmphinase 2 - Tamir; Recombinant amphinase 2 - Tamir; TMR-004

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alfacell Corporation
  • Developer Johns Hopkins University; National Institute of Allergy and Infectious Diseases; Tamir Biotechnology; United States Army Medical Research Institute of Infectious Diseases
  • Class Ribonucleases
  • Mechanism of Action Mitosis inhibitors; Ribonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections
  • No development reported Brain cancer; Cytomegalovirus infections; Dengue; Human papillomavirus infections; Severe acute respiratory syndrome; Yellow fever

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cytomegalovirus infections in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top